By Nikolaj Skydsgaard COPENHAGEN (Reuters) – Shares in Novo Nordisk rose more than 3% on Wednesday after the Danish drug developer delivered a better-than-expected earnings outlook for 2022 despite missing fourth quarter operating profit expectations. The world’s largest diabetes drug developer expects to generate sales growth of between 6% and 10% in local currencies in 2022 and deliver operating profit growth of 4% to 8%. “This reflects an underlying unchanged positive growth momentum for Novo Nordisk,” Sydbank analyst Soren Lontoft told Reuters, adding that he would be raising his estimates…